Availability of Program Application Instructions for the Title VII, Part C of the Act, Centers for Independent Living (CILs) To Expand COVID-19 Vaccine Access for People With Disabilities, 18536-18538 [2021-07290]
Download as PDF
<![CDATA[
18536
Federal Register / Vol. 86, No. 67 / Friday, April 9, 2021 / Notices
Respondents: 13,000; Total Annual
Responses: 13,000; Total Annual Hours:
4,290 (For policy questions regarding
this collection contact Luis Pons Perez
at 410–786–8557)
3. Type of Information Collection:
Extension of a currently approved
collection; Title of Information
Collection: Program Integrity II; Use: On
June 19, 2013, HHS published proposed
rule CMS–9957–P: Program Integrity:
Exchanges, SHOP, Premium
Stabilization Programs, and Market
Standards (78 FR 37302) (Program
Integrity Proposed Rule) which, among
other things, contained third party
disclosure requirements and data
collections that supported the oversight
of premium stabilization programs,
State Exchanges, and qualified health
plan (QHP) issuers in Federallyfacilitated Exchanges (FFEs). Parts of the
proposed rule were finalized as Patient
Protection and Affordable Care Act;
Program Integrity: Exchange, Premium
Stabilization Programs, and Market
Standards; Amendments to the HHS
Notice of Benefit and Payment
Parameters for 2014; Final Rule
(Program Integrity Final Rule II), 78 FR
25326 (October 24, 2013). This ICR
relates to a portion of the information
collection request (ICR) requirements set
forth in the final rule. Form Number:
CMS–10516 (OMB control number:
0938–1277); Frequency: Annually;
Affected Public: Private Sector, State,
Business, and Not-for Profits; Number of
Respondents: 428; Number of
Responses: 428; Total Annual Hours:
40,420. (For questions regarding this
collection, contact Joshua Van Drei at
(410–786–1659).
4. Type of Information Collection
Request: Revision of a currently
approved information collection; Title
of Information Collection: Medicare
Registration Application; Use:
Physicians and practitioners complete
the Medicare Enrollment Application—
Enrollment for Eligible Ordering,
Certifying Physicians and Other Eligible
Professionals if they are enrolling in
Medicare not to obtain Medicare billing
privileges but strictly to order, refer, or
certify certain Medicare items and
services. It is used by Medicare
contractors to collect data that helps
ensure the applicant has the necessary
credentials to order and certify certain
Medicare items and services.
The MAC establishes Medicare
Identification Numbers. The MACs store
these numbers and information in CMS’
Provider Enrollment, Chain and
Ownership System (PECOS). The
application is used by the CMS’
contractors to collect data ensures that
the applicant has the necessary
VerDate Sep<11>2014
17:45 Apr 08, 2021
Jkt 253001
information for unique identification.
The license numbers are validated
against state licensing websites. All the
license numbers are captured and stored
in the MAC database. Social Security
Numbers (SSNs) are validated against
the Social Security Administration
database (SSA) and only the valid
entries are allowed to proceed in the
process of getting a Medicare billing
number. Correspondence address and
contact information is captured to
contact the provider/supplier.
The collection and verification of this
information defends and protects our
beneficiaries from illegitimate
providers/suppliers. These procedures
also protect the Medicare Trust Fund
against fraud. It gathers information that
allow Medicare contractors to ensure
that the physician or eligible
professional is not sanctioned from the
Medicare and/or Medicaid program(s),
or debarred, or excluded from any other
Federal agency or program. The data
collected also ensures that the applicant
has the necessary credentials to order
and certify health care services. This is
sole instrument implemented for this
purpose. Form Number: CMS–855O
(OMB Control Number: 0938–1135);
Frequency: Occasionally; Affected
Public: Private Sector (Business or other
for-profits), State, Local, or Tribal
Governments; Number of Respondents:
448,000; Number of Responses: 24,000;
Total Annual Hours: 243,600. (For
questions regarding this collection
contact Kimberly McPhillips (410–786–
8438.)
5. Type of Information Collection
Request: Reinstatement without change
of a previously approved collection;
Title of Information Collection: Organ
Procurement Organization
Histocompatibility Laboratory Cost
Report; Use: The Form CMS–216–94
cost report is needed to determine
Organ Procurement Organization (OPO)/
Histocompatibility Lab (HL) reasonable
costs incurred in procuring and
transporting organs for transplant into
Medicare beneficiaries and
reimbursement due to or from the
provider. The reasonable costs of
procuring and transporting organs
cannot be determined for the fiscal year
until the OPO/HL files its cost report
and costs are verified by the Medicare
contractor. During the fiscal year, an
interim rate is established based on cost
report data from the previous year. The
OPO/HL bills the transplant hospital for
services rendered. The transplant
hospital pays interim payments,
approximating reasonable cost, to the
OPO/HL. The Form CMS–216–94 cost
report is filed by each OPO/HL at the
end of its fiscal year and there is a cost
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
report settlement to take into account
increases or decreases in costs. The cost
report reconciliation and settlement take
into consideration the difference
between the total reasonable costs
minus the total interim payments
received or receivable from the
transplant centers. Form Number: CMS–
216–94 (OMB Control number: 0938–
0102); Frequency: Annually; Affected
Public: Private Sector—Business or
other for-profits; Number of
Respondents: 95; Total Annual
Responses: 95; Total Annual Hours:
4,275 (For policy questions regarding
this collection contact Luann Piccione
at 410–786–5423)
Dated: April 6, 2021.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office
of Strategic Operations and Regulatory
Affairs.
[FR Doc. 2021–07342 Filed 4–8–21; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Community Living
Availability of Program Application
Instructions for the Title VII, Part C of
the Act, Centers for Independent
Living (CILs) To Expand COVID–19
Vaccine Access for People With
Disabilities
Title: Expanding Disabilities
Network’s (CILs) Access to COVID–19
Vaccines.
Announcement Type: Initial.
Statutory Authority: The statutory
authority for grants under this program
announcement is contained in Section
711 and Section 712 of the
Rehabilitation Act of 1973 [Pub. L. 93–
112] [As Amended Through Pub. L.
114–95, Enacted December 10, 2015].
Catalog of Federal Domestic
Assistance (CFDA) Number: 93.432.
DATES: The deadline date for the
submission of the Expanding
Disabilities Network’s (CILs) Access to
COVID–19 Vaccines is 11:59 p.m.
Eastern Time April 23, 2021.
I. Funding Opportunity Description
The Administration for Community
Living (ACL) announced a new funding
opportunity to increase vaccine access
for people with disabilities. With
funding and partnership support from
the Centers for Disease Control (CDC),
ACL is providing grants to disability
networks to provide critical services to
help communities combat COVID–19. A
leading priority of this joint effort is to
E:\FR\FM\09APN1.SGM
09APN1
Federal Register / Vol. 86, No. 67 / Friday, April 9, 2021 / Notices
ensure vaccines are equally accessible to
the disability population.
Approximately 61 million adults
living with in the U.S. have a disability,
representing approximately 26 percent
of the adult population. Disability alone
may not be related to increased risk for
contracting COVID–19 based on where
they live. Some people with disabilities
live in group settings which places them
at higher risk for acquiring COVID–19 in
comparison to people without
disabilities. People with disabilities may
also require close contact with direct
service providers, including personal
care attendants or other care providers,
who help with activities of daily living.
Moreover, many people with disabilities
have underlying health conditions (e.g.,
diabetes, heart disease, and obesity) that
increases the risk of severe illness due
to COVID–19. In addition, research also
found that people with Down Syndrome
are significantly more likely to be
hospitalized from COVID–19 than the
general population.
There are increasing reports of
barriers of unequal access in
communities to vaccinate people with
disabilities. For example, some people
with disabilities may experience
difficulties scheduling appointments,
communicating, obtaining accessible
transportation or require direct support
services to attend vaccination
appointments. Others living in the
community may be isolated or unable to
leave their home and may require inhome vaccination.
This funding opportunity is designed
to breakdown those barriers to expand
vaccine access in communities.
Examples of activities consistent with
the purpose of this funding are the
following:
• Education about the importance of
receiving a vaccine,
• Identifying people unable to
independently travel to a vaccination
site,
• Helping with scheduling a vaccine
appointment,
• Arranging or providing accessible
transportation,
• Providing companion/personal
support,
• Reminding people of their second
vaccination appointment if needed,
and/or,
• Providing technical assistance to
local health departments or other
entities on vaccine accessibility.
Awards authorized under Title VII,
Part C of the Rehabilitation Act shall be
provided funding under this
opportunity. Award recipients will be
required to submit annual progress
reports in the form of a written
summary on the activities conducted,
VerDate Sep<11>2014
17:45 Apr 08, 2021
Jkt 253001
challenges, successes, and lessons
learned. In addition, to show impact of
the grant awards, the grantee will
include the number of people served or
impacted by the services provided,
against each of the activities chosen to
be implemented. To be eligible to
receive this grant, the grantee must
submit a Letter of Assurance to ACL
containing all the assurances required,
(see below, ‘‘Section III. Eligibility
Criteria and Other Requirements’’ and
‘‘Section IV. Submission Information’’).
Part C CILs that do not complete
assurance requirements below, or
otherwise indicate no desire to receive
funds will be excluded from receiving
funds.
ACL may establish ad hoc dates based
on the need of the COVID–19 response,
e.g., to meet unanticipated issues related
to COVID–19 and/or to allow impacted
eligible applicants that missed the cutoff date to submit an application for
consideration. ACL intends to issue
initial notices of award as applications
are received prior to the application due
date to address urgent COVID–19
response needs. Second notices of
award are planned after the actual
number of applicants is finalized.
II. Award Information
1. Funding Instrument Type
These awards will be made in the
form of formula grants to Part C CILs.
2. Anticipated Total Funding per Budget
Period
Awards made under this
announcement have an estimated start
date of April 1, 2021 and an estimated
end date of December 31, 2022, for a 20month budget and performance period.
The total available funding for this
opportunity is $5,000,000. CILs who do
not complete assurance requirements
below, or otherwise indicate no desire
to receive funds will be excluded from
receiving funds. This will have the
effect of increasing the amount of funds
available for eventual recipients.
ACL has determined that if funding
were allocated based on previously
utilized formulas that a number of
grantees would receive funding that was
not sufficient to provide any substantive
work. As a result, ACL will be
distributing the $5,000,000 evenly to all
Part C grantees which equates to a
minimum award of $14,204
($5,000,000/352). This figure is based on
352 recipients and would rise if some
grantees refuse or are deemed ineligible.
Please note that all activities
allowable under this funding are also
allowable under CARES Act award. In
order to minimize unused funds
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
18537
grantees are encouraged to review their
current ability to utilize CARES Act
funds, remaining balances and future
plans when deciding whether or not to
submit for this additional funding.
III. Eligibility Criteria and Other
Requirements
1. Eligible Entities
The eligible entity for these awards is
designated by ACL as a Part C CIL.
2. Other Requirements
A. Letter of Assurance
A Letter of Assurance is required to be
submitted by the eligible entity in order
to receive an award. The Letter of
Assurance must include the following:
1. Assurance that the award recipient
is an entity designated as a Part C
funded CIL.
2. Assurance that funds will
supplement and not supplant existing
Part C funding.
3. Assurance that funds will be spent
in ways consistent with the purpose of
the funding in carrying out one or more
of the following activities:
• Education about the importance of
receiving a vaccine,
• Identifying people unable to
independently travel to a site,
• Helping with scheduling a vaccine
appointment,
• Arranging or providing accessible
transportation,
• Providing companion/personal
support,
• Reminding people of their second
vaccination appointment if needed,
and/or,
• Providing technical assistance to
local health departments or other
entities on vaccine accessibility.
4. Assurance that the award recipient
will do outreach to Aging and Disability
Resource Centers, University Centers for
Excellence in Developmental
Disabilities Education, Research, and
Service and State Councils on
Developmental Disabilities, to maximize
state coordination wherever possible.
5. Assurance to provide semi-annual
federal financial reports and annual
program reports that describes activities
conducted, challenges, successes, and
lessons learned. The written summary
will also include number of people
served or impacted by the services
provided.
B. DUNS Number
All grant applicants must obtain and
keep current a D–U–N–S number from
Dun and Bradstreet. It is a nine-digit
identification number, which provides
unique identifiers of single business
entities. The D–U–N–S number can be
E:\FR\FM\09APN1.SGM
09APN1
18538
Federal Register / Vol. 86, No. 67 / Friday, April 9, 2021 / Notices
obtained from: https://iupdate.dnb.com/
iUpdate/viewiUpdateHome.htm.
C. Intergovernmental Review
Executive Order 12372,
Intergovernmental Review of Federal
Programs, is not applicable to these
grant applications.
IV. Submission Information
1. Letter of Assurance
To receive funding, eligible entities
must provide a Letter of Assurance
containing all the information outlined
in Section III above.
Letters of Assurance should be
addressed to: Alison Barkoff, Acting
Administrator and Assistant Secretary
for Aging, Administration for
Community Living, 330 C Street SW,
Washington, DC 20201.
Letters of Assurance should be
submitted electronically via email to
your ACL program officer. The
following table identifies the designated
program officer against each of the 10
ACL regions:
ACL regions
Peter Nye—Program Officer .............................
Veronica Hogan .................................................
Jennifer Martin ...................................................
Kimball Gray ......................................................
2. Submission Dates and Times
To receive consideration, Letters of
Assurance must be submitted by 11:59
p.m. Eastern Time on April 23, 2021.
Letters of Assurance should be
submitted electronically via email and
have an electronic time stamp
indicating the date/time submitted.
VII. Agency Contacts
1. Programmatic and Submission Issues
Direct programmatic inquiries to
Program Officer found in the table in
‘‘Section IV. Submission Information.’’
2. Submission Issues
Direct inquiries regarding submission
of the Letters of Assurance to Program
Officer found in the table in ‘‘Section
IV. Submission Information.’’
Dated: April 5, 2021.
Alison Barkoff,
Acting Administrator and Assistant Secretary
for Aging.
Email/phone
Region II
• NY, NJ, PR, VI
Region V
• IL, IN, MI, MN, OH, WI
Region X
• AK, ID, OR, WA
Region I
• CT, MA, ME, NH, RI, VT
Region III
• DC, DE, MD, PA, VA, WV
Region VII
• IA, KS, MO, NE
Region IV
• AL, FL, GA, KY, MS, NC, SC, TN
Region VI
• AR, LA, OK, NM, TX
Region VIII
• CO, MT, UT, WY, ND, SD
Region IX
• CA, NV, AZ, HI, GU, CNMI, AS
peter.nye@acl.hhs.gov; 202–795–7606.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
grants to disability networks to provide
critical services to help communities
combat COVID–19. A leading priority of
this joint effort is to ensure vaccines are
equally accessible to the disability
population. Approximately 61 million
adults living with in the US have a
disability, representing approximately
26 percent of the adult population.
People with disabilities may have an
increased risk for contracting COVID–19
based on where they live or the services
they receive. Some people with
disabilities live in group settings, which
places them at higher risk for acquiring
COVID–19 in comparison to people
without disabilities. People with
disabilities may also require close
contact with direct service providers,
including personal care attendants or
other care providers, who help with
activities of daily living. Moreover,
many people with disabilities have
underlying health conditions (e.g.,
diabetes, heart disease, and obesity) that
increases the risk of severe illness due
to COVID–19. In addition, research also
found that people with Down Syndrome
are significantly more likely to be
hospitalized from COVID–19 than the
general population.
Administration for Community Living
Availability of Program Application
Instructions for the Protection and
Advocacy Systems Network To
Expand COVID–19 Vaccine Access for
People With Disabilities
Title: Expanding Disabilities
Network’s (Protection and Advocacy
Systems) Access to COVID–19 Vaccines.
Announcement Type: Initial.
Statutory Authority: Subtitle C of the
Developmental Disabilities Assistance
and Bill of Rights Act of 2000 (DD Act).
Catalog of Federal Domestic
Assistance (CFDA) Number: 93.630.
DATES: The deadline date for the
submission of the Expanding
Disabilities Network’s (Protection and
Advocacy Systems) Access to COVID–
19 Vaccines is 11:59 p.m. Eastern Time
April 23, 2021.
SUPPLEMENTARY INFORMATION:
[FR Doc. 2021–07290 Filed 4–8–21; 8:45 am]
I. Funding Opportunity Description
BILLING CODE 4154–01–P
The Administration for Community
Living (ACL) announced a new funding
opportunity to increase vaccine access
for people with disabilities. With
funding and partnership support from
the Centers for Disease Control and
Prevention (CDC), ACL is providing
VerDate Sep<11>2014
17:45 Apr 08, 2021
Jkt 253001
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
veronica.hogan@acl.hhs.gov; 202–795–7365.
jennifer.martin@acl.hhs.gov; 202–795–7399.
kimball.gray@acl.hhs.gov; 202–795–7353.
E:\FR\FM\09APN1.SGM
09APN1
]]>Agencies
[Federal Register Volume 86, Number 67 (Friday, April 9, 2021)]
[Notices]
[Pages 18536-18538]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-07290]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Administration for Community Living
Availability of Program Application Instructions for the Title
VII, Part C of the Act, Centers for Independent Living (CILs) To Expand
COVID-19 Vaccine Access for People With Disabilities
Title: Expanding Disabilities Network's (CILs) Access to COVID-19
Vaccines.
Announcement Type: Initial.
Statutory Authority: The statutory authority for grants under this
program announcement is contained in Section 711 and Section 712 of the
Rehabilitation Act of 1973 [Pub. L. 93-112] [As Amended Through Pub. L.
114-95, Enacted December 10, 2015].
Catalog of Federal Domestic Assistance (CFDA) Number: 93.432.
DATES: The deadline date for the submission of the Expanding
Disabilities Network's (CILs) Access to COVID-19 Vaccines is 11:59 p.m.
Eastern Time April 23, 2021.
I. Funding Opportunity Description
The Administration for Community Living (ACL) announced a new
funding opportunity to increase vaccine access for people with
disabilities. With funding and partnership support from the Centers for
Disease Control (CDC), ACL is providing grants to disability networks
to provide critical services to help communities combat COVID-19. A
leading priority of this joint effort is to
[[Page 18537]]
ensure vaccines are equally accessible to the disability population.
Approximately 61 million adults living with in the U.S. have a
disability, representing approximately 26 percent of the adult
population. Disability alone may not be related to increased risk for
contracting COVID-19 based on where they live. Some people with
disabilities live in group settings which places them at higher risk
for acquiring COVID-19 in comparison to people without disabilities.
People with disabilities may also require close contact with direct
service providers, including personal care attendants or other care
providers, who help with activities of daily living. Moreover, many
people with disabilities have underlying health conditions (e.g.,
diabetes, heart disease, and obesity) that increases the risk of severe
illness due to COVID-19. In addition, research also found that people
with Down Syndrome are significantly more likely to be hospitalized
from COVID-19 than the general population.
There are increasing reports of barriers of unequal access in
communities to vaccinate people with disabilities. For example, some
people with disabilities may experience difficulties scheduling
appointments, communicating, obtaining accessible transportation or
require direct support services to attend vaccination appointments.
Others living in the community may be isolated or unable to leave their
home and may require in-home vaccination.
This funding opportunity is designed to breakdown those barriers to
expand vaccine access in communities. Examples of activities consistent
with the purpose of this funding are the following:
Education about the importance of receiving a vaccine,
Identifying people unable to independently travel to a
vaccination site,
Helping with scheduling a vaccine appointment,
Arranging or providing accessible transportation,
Providing companion/personal support,
Reminding people of their second vaccination appointment
if needed, and/or,
Providing technical assistance to local health departments
or other entities on vaccine accessibility.
Awards authorized under Title VII, Part C of the Rehabilitation Act
shall be provided funding under this opportunity. Award recipients will
be required to submit annual progress reports in the form of a written
summary on the activities conducted, challenges, successes, and lessons
learned. In addition, to show impact of the grant awards, the grantee
will include the number of people served or impacted by the services
provided, against each of the activities chosen to be implemented. To
be eligible to receive this grant, the grantee must submit a Letter of
Assurance to ACL containing all the assurances required, (see below,
``Section III. Eligibility Criteria and Other Requirements'' and
``Section IV. Submission Information''). Part C CILs that do not
complete assurance requirements below, or otherwise indicate no desire
to receive funds will be excluded from receiving funds.
ACL may establish ad hoc dates based on the need of the COVID-19
response, e.g., to meet unanticipated issues related to COVID-19 and/or
to allow impacted eligible applicants that missed the cut-off date to
submit an application for consideration. ACL intends to issue initial
notices of award as applications are received prior to the application
due date to address urgent COVID-19 response needs. Second notices of
award are planned after the actual number of applicants is finalized.
II. Award Information
1. Funding Instrument Type
These awards will be made in the form of formula grants to Part C
CILs.
2. Anticipated Total Funding per Budget Period
Awards made under this announcement have an estimated start date of
April 1, 2021 and an estimated end date of December 31, 2022, for a 20-
month budget and performance period.
The total available funding for this opportunity is $5,000,000.
CILs who do not complete assurance requirements below, or otherwise
indicate no desire to receive funds will be excluded from receiving
funds. This will have the effect of increasing the amount of funds
available for eventual recipients.
ACL has determined that if funding were allocated based on
previously utilized formulas that a number of grantees would receive
funding that was not sufficient to provide any substantive work. As a
result, ACL will be distributing the $5,000,000 evenly to all Part C
grantees which equates to a minimum award of $14,204 ($5,000,000/352).
This figure is based on 352 recipients and would rise if some grantees
refuse or are deemed ineligible.
Please note that all activities allowable under this funding are
also allowable under CARES Act award. In order to minimize unused funds
grantees are encouraged to review their current ability to utilize
CARES Act funds, remaining balances and future plans when deciding
whether or not to submit for this additional funding.
III. Eligibility Criteria and Other Requirements
1. Eligible Entities
The eligible entity for these awards is designated by ACL as a Part
C CIL.
2. Other Requirements
A. Letter of Assurance
A Letter of Assurance is required to be submitted by the eligible
entity in order to receive an award. The Letter of Assurance must
include the following:
1. Assurance that the award recipient is an entity designated as a
Part C funded CIL.
2. Assurance that funds will supplement and not supplant existing
Part C funding.
3. Assurance that funds will be spent in ways consistent with the
purpose of the funding in carrying out one or more of the following
activities:
Education about the importance of receiving a vaccine,
Identifying people unable to independently travel to a
site,
Helping with scheduling a vaccine appointment,
Arranging or providing accessible transportation,
Providing companion/personal support,
Reminding people of their second vaccination appointment
if needed, and/or,
Providing technical assistance to local health departments
or other entities on vaccine accessibility.
4. Assurance that the award recipient will do outreach to Aging and
Disability Resource Centers, University Centers for Excellence in
Developmental Disabilities Education, Research, and Service and State
Councils on Developmental Disabilities, to maximize state coordination
wherever possible.
5. Assurance to provide semi-annual federal financial reports and
annual program reports that describes activities conducted, challenges,
successes, and lessons learned. The written summary will also include
number of people served or impacted by the services provided.
B. DUNS Number
All grant applicants must obtain and keep current a D-U-N-S number
from Dun and Bradstreet. It is a nine-digit identification number,
which provides unique identifiers of single business entities. The D-U-
N-S number can be
[[Page 18538]]
obtained from: https://iupdate.dnb.com/iUpdate/viewiUpdateHome.htm.
C. Intergovernmental Review
Executive Order 12372, Intergovernmental Review of Federal
Programs, is not applicable to these grant applications.
IV. Submission Information
1. Letter of Assurance
To receive funding, eligible entities must provide a Letter of
Assurance containing all the information outlined in Section III above.
Letters of Assurance should be addressed to: Alison Barkoff, Acting
Administrator and Assistant Secretary for Aging, Administration for
Community Living, 330 C Street SW, Washington, DC 20201.
Letters of Assurance should be submitted electronically via email
to your ACL program officer. The following table identifies the
designated program officer against each of the 10 ACL regions:
------------------------------------------------------------------------
ACL regions Email/phone
------------------------------------------------------------------------
Peter Nye--Program Officer...... Region II [email protected]
NY, NJ, gov; 202-795-
PR, VI. 7606.
Region V
IL, IN,
MI, MN, OH, WI.
Region X
AK, ID,
OR, WA.
Veronica Hogan.................. Region I [email protected]
CT, MA, .hhs.gov; 202-795-
ME, NH, RI, VT. 7365.
Region III
DC, DE,
MD, PA, VA, WV.
Region VII
IA, KS,
MO, NE.
Jennifer Martin................. Region IV [email protected]
AL, FL, l.hhs.gov; 202-
GA, KY, MS, NC, 795-7399.
SC, TN.
Region VI
AR, LA,
OK, NM, TX.
Kimball Gray.................... Region VIII [email protected]
CO, MT, hs.gov; 202-795-
UT, WY, ND, SD. 7353.
Region IX
CA, NV,
AZ, HI, GU, CNMI,
AS.
------------------------------------------------------------------------
2. Submission Dates and Times
To receive consideration, Letters of Assurance must be submitted by
11:59 p.m. Eastern Time on April 23, 2021. Letters of Assurance should
be submitted electronically via email and have an electronic time stamp
indicating the date/time submitted.
VII. Agency Contacts
1. Programmatic and Submission Issues
Direct programmatic inquiries to Program Officer found in the table
in ``Section IV. Submission Information.''
2. Submission Issues
Direct inquiries regarding submission of the Letters of Assurance
to Program Officer found in the table in ``Section IV. Submission
Information.''
Dated: April 5, 2021.
Alison Barkoff,
Acting Administrator and Assistant Secretary for Aging.
[FR Doc. 2021-07290 Filed 4-8-21; 8:45 am]
BILLING CODE 4154-01-P
